ClinicalTrials.gg
CompletedNCT06595121BUNIPILOTUpdated Nov 8, 2024

Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)

A Phase 1 interventional study of budesonide and budesonide in Healthy, sponsored by Unither Pharmaceuticals, France. Completed at 1 site in Turkey. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Unither Pharmaceuticals, France · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study aims to demonstrate the bioequivalence between the formulation of Budesonide 1mg/2mL nebuliser suspension (IMP 08P1707F0) relaive to the reference product Pulmicort(r) 1.0mg/2mL suspension.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Unither Pharmaceuticals, France is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, Caucasian, male and female (16 male, 8 female) subjects 18 - 55 years of age
  • within the range of ≥ 18.5 and ≤ 30.0 kg/m2
  • Female subjects of childbearing potential1) agree to undergo pregnancy tests and to use at least an acceptable effective method during the study and until 90 days after study end
  • Negative Covid-19 test result
  • Findings within the range of clinical acceptability in medical history (or the clinical investigator considers the deviation to be irrelevant for the purpose of the study)
  • Findings within the range of clinical acceptability in physical examination (or the clinical investigator considers the deviation to be irrelevant for the purpose of the study)
  • Laboratory values within the normal range (or the clinical investigator considers the deviation to be irrelevant for the purpose of the study)
  • Normal (ECG) or abnormalities which the clinical investigator does not consider a disqualification for participation in the study
  • Normal vital signs (normal blood pressure and heart rate measured under stabilised conditions at screening visit after at least 5 minutes of rest in sitting position: systolic blood pressure 100 - 140 mmHg, diastolic blood pressure 60 - 90 mmHg and heart rate 50 - 100 beats per minute; normal body temperature (Forehead, 35.5 °C - 37.0 °C)) or abnormalities which the clinical investigator does not consider a disqualification for participation in the study (...)

Exclusion criteria

Exclusion Criteria:

  • History of to the study drug or any related drugs or to any of the
  • History or presence of any cardiovascular, pulmonary, hepatobiliary, renal, haematological, gastrointestinal, endocrinologic, immunologic, dermatologic, neurological, psychiatric, metabolic, musculoskeletal, malignant disease or eye disorders as glaucoma or a family history of glaucoma
  • Clinically significant abnormal laboratory values
  • Clinically significant findings
  • Clinically significant vital signs (...)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    IMP 08P1707F0 without charcoal

    Budesonide 1mg/2mL nebuliser suspension (08P1707F0) without charcoal

    Drug: budesonide

  • Experimental
    IMP 08P1707F0 with charcoal

    Budesonide 1mg/2mL nebuliser suspension (08P1707F0) with charcoal

    Drug: budesonide · Other: Activated Charcoal

  • Active comparator
    Pulmicort 1.0mg/2mL Suspension

    Pulmicort 1.0mg/2mL Suspension (First administration)

    Drug: budesonide

  • Active comparator
    Pulmicort 1.0mg/ML suspension (second administration)

    Pulmicort 1.0mg/ML suspension (second administration)

    Drug: budesonide

Interventions

  • Budesonide 1 mg/2mL nebuliser suspension

    Also known as: IMP 08P1707F0

  • Pulmicort(r) 1 mg/2mL nebuliser suspension

  • OtherActivated Charcoal

    suspension of 10g activated charcoal slurried in 70mL of water

06

What researchers measure

Primary outcomes

  1. Cmax of budesonide for the differents arms

    The maximum concentration in plasma among observed concentrations at pre-specified time points

    Time frame: predose, 0.05, .010, 0.17, 0.25, 0.33, 0.42, 0.50, 0.67, 1.00, 1.33, 1.67, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00 and 24.00 hours

  2. AUC 0-t of budesonide for the differents arms

    The area under the curve of plasma concentration versus time curve from time O to the last measured concentration

    Time frame: predose, 0.05, .010, 0.17, 0.25, 0.33, 0.42, 0.50, 0.67, 1.00, 1.33, 1.67, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00 and 24.00 hours

Secondary outcomes

  1. AUC 0-∞ of budesonide for the differents arms

    Time frame: predose, 0.05, .010, 0.17, 0.25, 0.33, 0.42, 0.50, 0.67, 1.00, 1.33, 1.67, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00 and 24.00 hours

  2. AUC t-∞ of budesonide for the differents arms

    Time frame: predose, 0.05, .010, 0.17, 0.25, 0.33, 0.42, 0.50, 0.67, 1.00, 1.33, 1.67, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00 and 24.00 hours

  3. AUC O-30 min of budesonide for the differents arms

    Time frame: predose, 0.05, .010, 0.17, 0.25, 0.33, 0.42 and 0.50 hours

  4. t max of budesonide for the differents arms

    Time frame: predose, 0.05, .010, 0.17, 0.25, 0.33, 0.42, 0.50, 0.67, 1.00, 1.33, 1.67, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00 and 24.00 hours

  5. t 1/2 of budesonide for the differents arms

    Time frame: predose, 0.05, .010, 0.17, 0.25, 0.33, 0.42, 0.50, 0.67, 1.00, 1.33, 1.67, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00 and 24.00 hours

  6. AUC O-15 min of budesonide for the differents arms

    Time frame: predose, 0.05, .010, 0.17 and 0.25 hours

  7. λz of budesonide for the differents arms

    λz Elimination rate constant (calculated by log linear regression of concentrations observed during the terminal phase of elimination)

    Time frame: predose, 0.05, .010, 0.17, 0.25, 0.33, 0.42, 0.50, 0.67, 1.00, 1.33, 1.67, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00 and 24.00 hours

  8. Incidence of treatment-related adverse events

    Occurence and severity of adverse events (serious and non serious adverse events)

    Time frame: up to 24 hours

07

Study locations

1 site
  • Farmagen IKU Merkezi
    Gaziantep, 27000, Turkey
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: After the end of study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Sep 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2024
First posted
Sep 19, 2024
StartActual
Aug 13, 2024
Primary completionActual
Sep 16, 2024
CompletionActual
Sep 16, 2024
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06595121
Lead sponsor
Unither Pharmaceuticals, France
Collaborators
Analytical Clinical Concepts (ACC GmbH)
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Aug 13, 2024
Primary completion
Sep 16, 2024
Completion
Sep 16, 2024
Last update
Nov 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion